# **Special Issue**

# Molecular Genomics of Oral Submucous Fibrosis Pathology

### Message from the Guest Editor

We are excited to invite you to contribute scientific articles for the upcoming Special Issue of *Biomedicines*. We encourage submission under the categories of original research articles, reviews, and perspectives. Your contributions will significantly contribute to the growing body of knowledge in this field. Key themes for submissions include, but are not limited to, the following:

- Molecular basis of and signaling pathways in OSF.
- Gene expression patterns using advanced sequencing technologies in OSF.
- Immune biomarkers of OSF.
- Epigenetic landscape of OSF.
- Biomarkers and therapeutic approaches for managing OSF and improving patient outcomes.
- Clinical applications of novel research.

Submission guidelines and further details can be found on our website. We look forward to receiving your insightful contributions and working towards the collective progress in unraveling the complexities of Oral Submuçous Fibrosis.

#### **Guest Editor**

Dr. Sanjit Mukherjee

National Institutes of Health (NIH), Bethesda, MD 20892, USA

#### Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/227014

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





## **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).